Vanta achieves FedRAMP 20x Class C Certification for Government Cloud

1 min read     Updated on 10 Jul 2026, 12:09 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Vanta has achieved FedRAMP 20x Class C Certification for its Government Cloud offering, enabling federal agencies to use its automated trust management platform for continuous compliance. The certification supports IT modernization and resiliency requirements. Carahsoft Technology Corp distributes Vanta's solutions through multiple government contract vehicles.

powered bylight_fuzz_icon
45167982

*this image is generated using AI for illustrative purposes only.

Vanta and Carahsoft Technology Corp announced on July 09, 2026, that Vanta has achieved Federal Risk and Authorization Management Program (FedRAMP) Class C Certification through the 20x pathway for its Government Cloud offering. This certification enables federal agencies to leverage Vanta's automated trust management platform to enhance continuous compliance, streamline risk management, and increase visibility across security ecosystems. The authorization supports the Federal Government’s IT modernization and resiliency requirements.

Morgan Kaplan, Head of Public Sector at Vanta, stated that achieving FedRAMP 20x Class C Certification represents a significant milestone. The platform helps government vendors and agencies strengthen compliance and risk management across complex cybersecurity environments. It supports more than 35 frameworks, including CMMC, NIST 800-53, FedRAMP, and SOC 2, utilizing AI and automation to reduce manual effort and improve efficiency.

Carahsoft serves as Vanta’s Public Sector distributor, providing government agencies with streamlined access to Vanta’s agentic trust platform, solutions, services, and training. Brian O’Donnell, Vice President of Cybersecurity Solutions at Carahsoft, emphasized that the milestone underscores a shared commitment to advancing modern, scalable compliance approaches across the public sector.

Vanta’s solutions are available through various contract vehicles held by Carahsoft. These include SEWP V contracts NNG15SC03B and NNG15SC27B, NASPO ValuePoint Master Agreement #AR2472, TIPS Contract #220105, OMNIA Partners Contract #R240303, E&I Contract #EI00063~2021MA, and The Quilt Master Service Agreement Number MSA05012019-F.

Contract Vehicles

Contract Name Contract Number
SEWP V NNG15SC03B, NNG15SC27B
NASPO ValuePoint Master Agreement #AR2472
TIPS Contract #220105
OMNIA Partners Contract #R240303
E&I Contract #EI00063~2021MA
The Quilt Master Service Agreement MSA05012019-F

Historical Stock Returns for Vanta Bioscience

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%0.0%0.0%+27.15%-10.60%-81.73%

How will FedRAMP Class C Certification impact Vanta's competitive positioning against established compliance vendors in the federal market?

What specific federal agencies or sectors are expected to be the early adopters of Vanta's Government Cloud offering?

How might this certification influence Vanta's partnerships with other government contractors or systems integrators?

Vanta Bioscience board to consider FY26 audited results on May 30

1 min read     Updated on 26 May 2026, 01:58 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Vanta Bioscience Limited's board is set to meet on May 30, 2026, to approve the audited financial results for the financial year and half year ended March 31, 2026. The meeting will also review the statutory auditors' reports. The trading window for designated personnel remains closed from April 01, 2026, to June 1, 2026.

powered bylight_fuzz_icon
41329712

*this image is generated using AI for illustrative purposes only.

Vanta Bioscience Limited will convene a board meeting on May 30, 2026, to approve the standalone and consolidated audited financial results for the financial year and half year ended March 31, 2026. The meeting is scheduled to take place at 6:00 PM at the company's registered office in Secunderabad. The board will also take note of the audit reports issued by the statutory auditors regarding these financial statements.

Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company intimated the stock exchanges regarding this meeting. The approval of the audited results is a key regulatory requirement for the disclosure of the company's financial performance for FY26.

In continuation of a previous intimation dated March 24, 2026, the company announced that the trading window for all designated persons under its Insider Trading Policy will remain closed. This closure is effective from April 01, 2026, until June 1, 2026, inclusive of both dates, to ensure compliance with insider trading regulations during the period of financial result announcements.

The board's decision on the financial results will provide clarity on the company's fiscal health for the full year and the second half of FY26. The statutory auditors' reports will accompany the results, offering an independent assessment of the financial statements.

Key Meeting Details

Detail Information
Meeting Date May 30, 2026
Meeting Time 6:00 PM
Venue Registered Office, Secunderabad
Agenda Audited Financial Results for FY26 and Half Year ended March 31, 2026
Trading Window Closure April 01, 2026 to June 1, 2026

Historical Stock Returns for Vanta Bioscience

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%0.0%0.0%+27.15%-10.60%-81.73%

How will the FY26 financial results influence Vanta Bioscience's capital allocation strategy for the upcoming fiscal year?

What market reaction is anticipated regarding the company's performance in the second half of FY26 compared to the first half?

Are there potential strategic partnerships or expansion plans expected to be unveiled alongside the financial results?

More News on Vanta Bioscience

1 Year Returns:-10.60%